In 2015, a phase II random control trails (RCT) of teprasiran, which was a siRNA (QPI-1002) and was designed to restrict p53-induced apoptosis, revealed that its administration could reduce the incidence, severity, and duration of early acute kidney injury (AKI) in high-risk patients undergoing cardiac surgery at day 90 [234]. Here, TP53 is linked to acute kidney injury.